Home
Site Search
Use small fonts Use medium fonts Use large fonts Email link to page

Resources

Related expertise

Canadian Life Science Law Blog Round-Up - March 2017

Published: 03/08/2017

By Cameron A. Mingay, Emily Larose, A. Chandimal Nicholas, Steven Kennedy, Jacqueline Richards

In This Issue

  1. Canada’s Excessive Pricing Regulations Survive Another Constitutional Challenge
  2. Health Canada Announces Random Testing of Medical Cannabis for Prohibited Pest Control Product Use
  3. Have Your Say on Federal Food Regulatory Change: Consultation Open On Draft Safe Food For Canadian Regulations
  4. To Engage or Not to Engage: Guidance on Motions to Strike a Within Application
  5. January 2017 Deal Round-Up
  6. Canada’s Cannabis Opportunity in the Era of Trump
  7. Proposed Changes in Personal Use Importation of Pest Control Products

Canada’s Excessive Pricing Regulations Survive Another Constitutional Challenge

By Steven Kennedy

The Patented Medicine Prices Review Board (the PMPRB) commenced a proceeding against Alexion Pharmaceuticals Inc. (Alexion) in respect of Alexion’s drug, SOLIRIS (eculizumab), which is used to treat rare and devastating blood and genetic conditions. The PMPRB claimed and successfully argued that Alexion was selling Soliris at an excessive price, under sections 82 and 85 of the Patent Act.

Read More

Top

Health Canada Announces Random Testing of Medical Cannabis for Prohibited Pest Control Product Use

By Emily Larose

In an announcement earlier today, Health Canada advised that it will be conducting random testing of medical cannabis products produced by licensed producers.

Read More

Top

Have Your Say on Federal Food Regulatory Change: Consultation Open On Draft Safe Food For Canadian Regulations

By Emily Larose

In January 2017, draft regulations under the Safe Food For Canadians Act (which was passed in November 2012) were published.

Read More

Top

To Engage or Not to Engage: Guidance on Motions to Strike a Within Application

By A. Chandimal Nicholas

The Federal Court has reaffirmed and clarified how a pharmaceutical brand company should respond to a generic company’s motion to strike an application for abuse of process under s. 6(5)(b) of the Patented Medicines (Notice of Compliance) Regulations.

Read More

Top

January 2017 Deal Round-Up

By Cameron A. Mingay

The following is a summary of major deals in the life science space that closed or were announced as closed in January 2017. Vancouver-based Quark Venture Inc., through its Global Health Sciences Venture Fund, continued to be an active investor, with investments made both in Canada and the United States in the month of January 2017.

Read More

Top

Canada’s Cannabis Opportunity in the Era of Trump

By Jacqueline Richards

Although the United States government’s attitudes toward cannabis have eased in recent years, the election of President Donald Trump has generated renewed uncertainty surrounding the future of the U.S. cannabis market. Canada, conversely, will very likely soon be one of the first industrialized countries with fully legalized recreational and medical cannabis, and investment in the Canadian cannabis market has been unprecedented.

Read More

Top

Proposed Changes in Personal Use Importation of Pest Control Products

By Emily Larose

Earlier this week, Health Canada announced proposed changes to the Pest Control Products Regulations that would limit the ability of individuals to import unregistered pesticides for personal use.

Read More

Top